Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes☆☆,
Keywords
Cited by (0)
- ☆☆
These results were presented as an abstract at the European Association for the Study of Diabetes Annual Meeting, Lisbon, Portugal, September 14, 2011.
Conflict of interest: R.R.H. is a government employee who received financial support to conduct the study, serves as a consultant and/or on the Advisory Board for Amgen, AstraZeneca, Intarcia Therapeutics, Inc., Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Eli Lilly and Company, Johnson & Johnson, Novo Nordisk Inc., Merck, Roche/Genentech, Sanofi, Medtronic, Daiichi Sankyo, and Elcelyx Therapeutics Inc., and has received grant/research support as the principle investigator from AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Sanofi, and Medtronic. J.R. received financial support to conduct the study, has served on scientific advisory boards and received honoraria/consulting fees from Amylin Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Daiichi Sankyo, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, MannKind Corporation, Novartis, Novo Nordisk, Pfizer, Inc., Roche, Sanofi, and Takeda Pharmaceuticals North America, Inc., and has also received grants/research support from Amylin Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly and Company, Forest Laboratories, GlaxoSmithKline, Johnson & Johnson, MannKind Corporation, Merck, Novartis, Novo Nordisk, Pfizer, Inc., Roche, Sanofi, and Takeda Pharmaceuticals North America, Inc. D.L. is an employee of Medpace, which was the contract research organization for this trial. T.A. and M.A.B. are employees of Intarcia Therapeutics, Inc. K.L. was an employee of Intarcia Therapeutics, Inc. at the time this study was conducted. No other potential conflicts of interest relevant to this article were reported.